Status:
WITHDRAWN
Lorazepam Effects on Neuroimaging Measures
Lead Sponsor:
Northwell Health
Conditions:
Lorazepam
Neuroimaging
Eligibility:
All Genders
18-40 years
Phase:
EARLY_PHASE1
Brief Summary
This within-subject, double blind, randomized controlled study will investigate the effects of a widely used benzodiazepine (BZD), lorazepam, on various neuroimaging measures. The investigators will b...
Eligibility Criteria
Inclusion
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 18-40
- In general good health as evidenced by medical history
- Ability to take oral medication and be willing to adhere to the study medication regimen
- For women of reproductive potential, negative pregnancy test and agreement to use a medically accepted birth control method.
Exclusion
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Pregnancy or lactation
- Contraindications to MR imaging (i.e. pacemaker)
- Known allergic reactions to components of the lorazepam
- Current smoker or tobacco use
- Concurrent use of any psychotropic medications, anticonvulsants, opioids or any other medication with effects on the CNS.
- Acute narrow-angle glaucoma
- Current or past history of a substance use disorder and/or a positive urine toxicology test.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04671836
Start Date
January 1 2022
End Date
December 1 2022
Last Update
May 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Zucker Hillside Hospital
Glen Oaks, New York, United States, 11004